Nano-X Imaging (NNOX) is an Israel-based medical imaging technology company seeking to make advanced 3D imaging more accessible and affordable. Its core differentiator is a proprietary digital X-ray source, the Nanox.SOURCE, which underpins the Nanox.ARC family of multi-source digital tomosynthesis systems. These systems aim to bridge the gap between conventional 2D X-rays and full computed tomography (CT) scans, delivering meaningful 3D imaging at lower cost and radiation dose.
The company's market positioning rests on an end-to-end ecosystem: the Nanox.ARC hardware, a cloud-based platform (Nanox.CLOUD), AI-driven diagnostic software (Nanox.AI), and a decentralized teleradiology marketplace (Nanox.MARKETPLACE) through its USARAD subsidiary. This integrated approach targets underserved and cost-constrained settings where expensive CT systems are often impractical. I also checked this using Tickeron’s AI Screener to see how NNOX compares to others in the industry.
Structurally, NNOX competes against established imaging giants with deep distribution networks and entrenched hospital relationships. Its competitive edge therefore depends less on displacing CT outright and more on capturing a distinct middle tier of imaging demand. The medium-term outlook hinges on whether the FDA-cleared Nanox.ARC X can convert clinical demonstrations into recurring, profitable sales and whether international regulatory approvals broaden the addressable market.
Several forward-looking events could shape investor sentiment. The formal commercial launch of the Nanox.ARC X at the RSNA 2025 meeting marked the system's first full-scale exposure to the radiology community, and follow-through orders from that visibility represent an important near-term catalyst.
Upcoming quarterly earnings releases will be pivotal. In the third quarter of 2025, the company reported revenue of approximately $3.4 million with a statutory loss of $0.21 per share, roughly in line with expectations. Analysts subsequently raised their 2026 revenue estimates to about $31.6 million, implying roughly 157% growth, while the average price target ticked up about 5% to approximately $8.15.
Regulatory milestones also loom large. Broader clearance for additional clinical indications and international approvals could materially expand the addressable population. Development of a pulmonary nodule AI solution and new standalone AI tools for aortic valve calcification and body composition measurements signal a deepening product pipeline that could enhance recurring software revenue. From what I see, these pipeline updates merit close attention.
On analyst ratings, coverage remains constructive but cautious. D. Boral Capital has maintained a Buy recommendation, Cantor Fitzgerald has reiterated Buy, and Alliance Global Partners has held a Buy stance, though price targets have been revised over time. The consensus profile leans positive, but the wide spread between the most bullish and most bearish targets reflects genuine uncertainty about commercial execution.
Nano-X Imaging's trajectory is sensitive to several macroeconomic and industry dynamics. Interest rates matter directly: as a pre-profitability growth company, NNOX's valuation is more exposed to changes in discount rates than that of a mature, cash-generating medical device maker. A persistently higher-rate environment can compress the present value of its longer-dated revenue potential.
Inflation and supply-chain costs influence hardware margins during the scaling phase. The company has explicitly flagged tariff policy, inflation, interest rates, and supply-chain costs as factors that could affect unit deployment. Healthcare capital expenditure cycles also play a role; hospitals facing budget pressure may defer discretionary imaging purchases, though the affordability of NNOX's systems could partially insulate it from that headwind.
Finally, the broader push toward value-based care and earlier, lower-cost diagnostics supports the demand case for tomosynthesis and AI-assisted screening. Technology adoption trends in artificial intelligence across radiology provide a structural tailwind, even as regulatory scrutiny of AI-enabled medical devices continues to evolve.
Looking toward 2026 and beyond, several structural themes will define Nano-X Imaging's outlook. The most consequential is the transition from a research-and-development story to a commercially scaling enterprise. Management's ambition to exceed 100 deployed units is a stepping stone; sustained, repeatable hardware sales and a growing installed base will be the true test of the model.
Cost structure evolution is equally important. The teleradiology segment already produces positive non-GAAP gross margins and helps offset losses elsewhere. As imaging system volume grows, investors will watch whether fixed manufacturing and R&D costs can be spread across a larger revenue base to drive margin sustainability.
Market expansion opportunities remain substantial in emerging and underserved regions, where lower-cost 3D imaging could unlock demand that conventional CT cannot serve economically. However, competitive threats from incumbents, the pace of international regulatory clearance, and the need for disciplined capital allocation amid ongoing cash burn will all shape long-term sentiment.
Analyst price targets, which currently cluster well above recent trading levels, should be viewed strictly as external expectations of long-term value rather than near-term forecasts. The trajectory will ultimately depend on execution: converting FDA clearance and clinical interest into durable, profitable revenue across the hardware, AI, and teleradiology businesses.
In my own research, I frequently use Tickeron’s AI Trend Prediction Engine to gauge short-term momentum for stocks like NNOX. This AI-powered tool provides forecasts on whether an asset may trend bullish, bearish, or sideways, along with historical context and alerts that help complement fundamental analysis. It has become a practical addition to my process for identifying potential breakouts or reversals without replacing core due diligence.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NNOX saw its Momentum Indicator move below the 0 level on November 17, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In 84 of the 93 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NNOX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NNOX entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NNOX's RSI Oscillator exited the oversold zone, 34 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for NNOX just turned positive on November 10, 2026. Looking at past instances where NNOX's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.260) is normal, around the industry mean (4.142). P/E Ratio (-0.140) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.266) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. NNOX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NNOX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which engages in the development of medical imaging systems
Industry MedicalNursingServices